Atefeh Abedini

Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit

Saeideh Mazloomzadeh, Shiva Khaleghparast, Behshid Ghadrdoost et al. · JAMA · 2021 · 653 citations · Full text

Pharmacy, Pharmacotherapy, Critical Care Pharmacology +16

Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies

Behnood Bikdeli, Azita H. Talasaz, Farid Rashidi et al. · Thrombosis Research · 2020 · 84 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial

Behnood Bikdeli, Azita H. Talasaz, Farid Rashidi et al. · Thrombosis and Haemostasis · 2021 · 79 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +17

WNT5a is required for normal ovarian follicle development and antagonizes gonadotropin responsiveness in granulosa cells by suppressing canonical WNT signaling

Atefeh Abedini, Gustavo Zamberlam, Évelyne Lapointe et al. · The FASEB Journal · 2015 · 73 citations · Full text

Life Sciences, Genetics, Molecular Biology +17

Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial

Reza Malekzadeh, Atefeh Abedini, Behzad Mohsenpour et al. · International Immunopharmacology · 2020 · 37 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +2